Keywords
SARS-CoV-2
Venous thromboembolism
Deep vein thrombosis
Prophylaxis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To search the literature for current evidence on the prophylaxis of venous thromboembolism in adult patients affected by COVID-19. Methods: This is an integrative literature review. The databases used were the Virtual Health Library (BVS), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medical Literature Analysis and Retrieval System Online (MEDLINE) through the National Library of Medicine and National Institutes of Health (PubMed) and SciVerse Scopus (Elsevier). The elaboration of the research question took place through the PICO strategy. The question arose: what are the prophylactic measures of venous thromboembolism in adult patients hospitalized with COVID-19? The literature search took place between August and November 2022. Initially, we found 501 articles. The selection of studies was carried out using the Rayyan® reference manager program. Results: The selected articles were included in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). And 23 articles that made up the final sample obeyed the inclusion and exclusion criteria, were exported and categorized in Microsoft Excel® 2016. Final considerations: Prophylactic or therapeutic anticoagulation were related to better clinical outcomes and a decrease in the mortality rate in this population.
References
ATALLAH B, et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia. 2021;76(3):327–35.
BARREIRO I, et al. Intrahospital Protocol for the Management of COVID-19 Disease in Adults. Acta Med Port. 2022;35(7–8):593–603.
BATISTA DR, et al. 2022 Uso de anticoagulantes em pacientes com COVID-19 : revisão sistemática “ viva ” e. J Bras Pneumol e Tisologia. 2022;48(4):1–10.
BRANDÃO SCS, et al. Severe COVID-19: Understanding the role of immunity, endothelium, and coagulation in clinical practice. J Vasc Bras. 2020;19:1–11.
BIKDELI V, et al. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost. 2021;122(1):131–41.
CASARIN ST, et al. Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health. J. nurs. health. 2020; 10(n.esp.): e20104031.
CHINDAMO MC, et al. Avaliação do risco de sangramento na profilaxia do tromboembolismo venoso. J Vasc Bras., 2021; 20.
CUKER A, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv., 2021; 5(3): 872–88.
CUNHA, et al. Incidence, diagnosis, treatment methods, and outcomes of clinically suspected venous thromboembolic disease in patients with COVID-19 in a quaternary hospital in Brazil. J Vasc Bras., 2021; 20: 1–7.
FARRAR JE, et al. Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19. J Thromb Thrombolysis, 2022; 53(2): 446–53.
FARIAS CP, et al. Trombose venosa profunda em pacientes com COVID-19: Rev Saúde. 2021;12(3):20–5.
FARHAT FCLG, et al. Avaliação da profilaxia da trombose venosa profunda em um hospital geral. J Vasc Bras., 2018;17(3):184–92.
HASAN SS, et al. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis, 2020; 50(4): 814–21.
IBA T, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost., 2019; 17(11): 1989–94.
KHALIL OAK e KHALIL SS. SARS-CoV-2: taxonomia, origem e constituição. Rev Med (São Paulo). 2020;99(5).
KYRIAKOULIS KG, et al. Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. Curr Vasc Pharmacol. 2021;20(1):96–110.
LAVÍNIO A, et al. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Crit Care. 2021; 25(1): 1–10.
LAZARIDIS D, et al. The Impact of Anticoagulation on COVID-19 (SARS CoV-2) Patient Outcomes: A Systematic Review. J PharmPract. 2022;35(6):1000-1006.
MAATMAN TK, et al. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. Crit Care Med. 2020;48(9):E783–90.
MELNYK BM e FINEOUT-OVERHOLT E. Evidence-based practice in nursing & healthcare: a guide to best practice [Internet]. Vol. 19, The Joanna Briggs Institute. 2013. p. 2013. Available from: https://books.google.com.br/books?id=EPaBEAAAQBAJ&printsec=frontcover&hl=pt-BR&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false. Acessado em: 10 de outubro de 2022.
OMS. 2022. Organização Mundial da Saúde (OMS). Painel da OMS sobre o Coronavírus. Disponível em: https://covid19.who.int/. Acessado em: 12 de abril de 2022.
OPAS. 2020. ORGANIZAÇÃO PAN-AMERICANA DE SAÚDE (OPAS). Histórico da Pandemia de Covid-19. Disponível em: https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19. Acessado em: 6 de março de 2022.
ORSI FA, et al. Diretrizes sobre diagnóstico, prevenção e tratamento de complicações tromboembólicas na Covid-19. Assoc Médica Bras.2020;1–22.
PARKS AL, et al. Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patternsand outcome sat 33 hospitals. PLoS ONE 2022. 17(5): e0266944.
RAMACCIOTTI E, et al. Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients. Crit Care Med. 2020;48(11):E1087–9.
RIYAHI S, et al. Predictors of acute deep venous thrombosis in patients hospitalized for COVID-19. Med (United States). 2021;100(38).
SADEGHIPOR P, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic. JAMA - J Am Med Assoc. 2021;325(16):1620–30.
SAMPAIO SML, et al. 2020 Atuação de enfermagem frente ao atendimento ao paciente hipertenso: uma revisão integrativa. Revista Eletrônica Acervo Saúde, n. 50, p. e3526, 18 jun. 2020.
SANT’ANNA LP, 2020. Anticoagulação na Covid-19, orientações da Sociedade Brasileira de Trombose e Hemostasia. Portal PEBMED. Disponível em: https://pebmed.com.br/anticoagulacao-na-covid-19-orientacoes-da-sociedade-brasileira-de-trombose-e-hemostasia/. Acessado em: 6 de março de 2022.
SIMPSON G e ROGERS M. A coleta em tempo real de dados sobre pacientes com COVID-19 e trombose e / ou hemorragia ajudou no desenvolvimento de diretrizes de profilaxia para tromboembolismo no Royal Surrey County Hospital durante a pandemia de COVID-19. R Coll Physicians. 2021;51–2.
SMS. 2020. SECRETARIA MUNICIPAL DE SAÚDE (SMS). Plano de ação para enfretamento da Covid-19. Brasil. Disponível em: https://www.prefeitura.sp.gov.br/cidade/secretarias/saude/acesso_a_informacao/index.php?p=295844. Acessado em: 6 de março de 2022.
SOBREIRA ML, et al. Anticoagulants as panacea in COVID-19 infection. J Vasc Bras. 2020;19:1–2.
SPYROPOULOS AC, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021;181(12):1612–20.
STAWIARSKI K. D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19. Thromb Res. 2021;201:151–3.
TACCONE FS, et al. Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients. Crit Care Med. 2020;48(11):E1087–90.
TAVARES LS e ORTIZ JV. Desenvolvimento da trombose em pacientes com e sem infecção pelo SARS-Cov-2 - revisão de literatura. Res Soc Dev. 2021;10(15):e410101522959.
VALLEJO OG, et al. Knowledge of thromboprophylaxis-COVID-19 in healthcare professionals in Spain. Med Fam Semer. 2021;47:361–8.
VAUGHN VN, et al. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized with COVID-19. JAMA Netw Open, 2021; 4(6): 1–13.
VOICU S, et al. Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19. J Infect., 2021; 82(5): 186-230.
XAVIER AR, et al. COVID-19: manifestações clínicas e laboratoriais na infecção pelo novo coronavírus. J Bras Patol e Med Lab., 2020; 56(5): 1–9.